Effect of 14-day Repeated Oral Doses of SAR302503 on Ventricular Repolarization, Compared to 1-day Placebo in Adult Patients With Refractory Solid Tumors

Trial Profile

Effect of 14-day Repeated Oral Doses of SAR302503 on Ventricular Repolarization, Compared to 1-day Placebo in Adult Patients With Refractory Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2014

At a glance

  • Drugs Fedratinib (Primary) ; Palonosetron
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Nov 2013 Planned End Date changed from 1 Apr 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 18 Nov 2013 Status changed from recruiting to discontinued, according to a Sanofi media release. Development of fedratinib has been discontinued.
    • 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top